Irbesartan Tablet
Product Images NDC 59746-447

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Irbesartan (NDC 59746-447). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Jubilant Cadista Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

150mgbottle

The label for Irbesartan Tablets, USP, 150 mg strength, containing 30 tablets. The label includes dosage form as tablets, oral route, with product identification markings and barcodes. Manufactured by Jubilant Generics Ltd. in India and marketed by Jubilant Cadista Pharmaceuticals Inc., USA. The label emphasizes storage instructions and dosing caution.*

FDA Label Image

300mgbottle

The label for Irbesartan Tablets USP indicates a strength of 300 mg. The packaging contains 30 oral tablets. It includes dosage storage instructions and highlights that it is a prescription-only medication. The labeler is Jubilant Cadista Pharmaceuticals Inc., with manufacturing by Jubilant Generics Ltd., India. The NDC number 59746-449-30 is shown along with the Cadista logo.*

FDA Label Image

75mgbottle

Label for Irbesartan Tablets, USP 75 mg oral tablets. Contains 30 tablets per package. The label shows the drug name and strength prominently, with a small image of the oblong white tablet engraved with "447" on one side and "C" on the other. It lists Jubilant Cadista Pharmaceuticals Inc. as the marketer and Jubilant Generics Ltd. in India as the manufacturer. Dosage and storage instructions are also included.*

FDA Label Image

Fig1

Two charts showing the placebo-subtracted reduction in trough systolic and diastolic blood pressure (SeSBP and SeDBP) plotted against Irbesartan dose (mg/day). Each chart presents data points and a curve fit illustrating the dose-response relationship for irbesartan tablets, highlighting blood pressure reduction efficacy across doses up to 900 mg/day.*

FDA Label Image

Figure3 (Figure3)

A line graph showing the cumulative event rate (%) over months of follow-up comparing Irbesartan, Amlodipine, and Placebo. The graph includes three lines: a solid bold line for Irbesartan, a thinner solid line for Amlodipine, and a dashed line for Placebo. An inset table displays relative risk (RR) and p-values comparing Irbesartan versus Placebo and Irbesartan versus Amlodipine.*

FDA Label Image

Structure (Structure)

Chemical structure of Irbesartan, showing its molecular arrangement with rings and side chains, consistent with the active ingredient of the oral tablet medication.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.